Crucell N.V. Revenue and Competitors
Estimated Revenue & Valuation
- Crucell N.V.'s estimated annual revenue is currently $21.2M per year.
- Crucell N.V.'s estimated revenue per employee is $208,186
Employee Data
- Crucell N.V. has 102 Employees.
- Crucell N.V. grew their employee count by -9% last year.
Crucell N.V.'s People
Name | Title | Email/Phone |
---|
Crucell N.V. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is Crucell N.V.?
Biotechnology; Pharmaceuticals
keywords:N/AN/A
Total Funding
102
Number of Employees
$21.2M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Crucell N.V. News
2022-04-19 - Global Tratamiento de la infección por H3N2 Mercado Análisis ...
AIMM Therapeutics BV, Aphios Corporation, Crucell NV, CSL Limited, Glide Pharmaceutical Technologies Limited, ILiAD Biotechnologies LLC,...
2022-04-17 - Influenza Virus Vaccine (H1N1) Market Size And Forecast | Butantan ...
... Biological Engineering Inc, Cantacuzino Institute Of Sera And Vaccines, Changchun Institute Of Biological Products And Crucell N.V..
2022-02-22 - Global HIV Vaccines Market Research Report to 2027 - Featuring AlphaVax, Crucell and Novartis Among Others - ResearchAndMarkets.com
Global HIV Vaccines Market Research Report to 2027 - Featuring AlphaVax, Crucell and Novartis Among Others - ResearchAndMarkets.com.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.3M | 102 | -7% | $100M |
#2 | $13.3M | 102 | -14% | $874.5M |
#3 | $27.4M | 102 | -8% | N/A |
#4 | $19.4M | 102 | 21% | $0.1M |
#5 | $23.1M | 102 | 9% | N/A |